Journal of Bioequivalence & Bioavailability

LCâ??MS/MS assay for Olanzapine in human plasma and its application to a bioequivalence study

6^th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit

August 17-19, 2015 Chicago, USA

Bhavinkumar Patel

Posters-Accepted Abstracts: J Bioequiv Availab

Abstract:

This paper describes a selective and sensitive assay for the determination of olanzapine (OLZ) in human plasma based on liquid
chromatography–tandem mass spectrometry (LC–MS/MS). The analyte and quetiapine as internal standard (IS) were extracted
from 200 mL plasma via solid phase extraction on Waters Oasis HLB cartridges. Chromatographic separation was achieved on an
ACE 5C18-300 column (100 mm, 4.6 mm, 5 mm) under isocratic conditions in a run time of 3.5 min. Mass spectrometric detection
involved electrospray ionization in the positive ion mode followed by multiple reaction monitoring (MRM) of the transitions at m/z
313/256 for OLZ and m/z 384/253 for the IS. The assay was linear in the range 0.10–40.0 ng/mL with a lower limit of quantitation
and limit of detection of 0.10 and 0.012 ng/mL respectively. Intra- and inter-day precision (as coefficient of variation) and relative
recovery were 5.0% and 490%, respectively.